Research letter: BRAF-inhibitor induced panniculitis- A systematic review Supplemental Material

Published: 10 August 2023| Version 1 | DOI: 10.17632/g8wrh8y3ws.1


To identify the common clinicopathological characteristics and management of BRAF-inhibitor induced panniculitis (BiP) we performed a systematic review that summarizes the current literature reporting the development of BiP. BiP appears to be a mild cutaneous adverse reaction that may benefit from symptomatic management without targeted therapy cessation. The following supplemental materials include a figure representing the schematic overview of our systematic review and tables of search terms and data points collected from the included reports. Additional tables of summarized patient characteristics and histopathology results, individual patient demographics and clinical findings, and the references of the studies included in this review.


Steps to reproduce

This protocol was registered with PROSPERO (Registration number CRD#42023391132) and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A librarian (D.N.) developed the search strategies with authors (Y.K., G.Z., and C.V.N), and ran searches in the following databases: OVID MEDLINE; Embase (Elsevier) and Cochrane (Wiley). All databases were searched without date or language filters applied. At least two authors (Y.K. and G.Z.) independently screened the titles and abstracts and conducted a full-text review of the articles using the web-based systematic review application, Rayyan. Articles were screened using the predetermined inclusion criteria: study provides at least 2 individual case data points including patient demographics, therapy management, clinical characteristics, or survival outcomes. This was in effort to reduce the risk of bias due to missing or non-reported information of the individual articles. Inconsistencies were resolved by discussion and consensus with a third author (C.V.N) available for additional input. The Oxford Centre for Evidence-Based Medicine Levels of Evidence guidelines were used to assess the quality of the articles.


Northwestern University


Systematic Review